ADVAGRAF®

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Liver Transplantation

Conditions

Liver Transplantation

Trial Timeline

Mar 22, 2016 → Dec 14, 2017

About ADVAGRAF®

ADVAGRAF® is a approved stage product being developed by Astellas Pharma for Liver Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT03423225. Target conditions include Liver Transplantation.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (3)

NCT IDPhaseStatus
NCT03423225ApprovedCompleted
NCT04761731ApprovedCompleted
NCT02161237ApprovedCompleted

Competing Products

20 competing products in Liver Transplantation

See all competitors
ProductCompanyStageHype Score
LanifibranorInventivaPhase 2
47
GODEX + PlaceboCelltrionPhase 3
77
peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirinChugai PharmaceuticalPhase 3
77
exatecan mesylateDaiichi SankyoPhase 2
52
TacrolimusAstellas PharmaPre-clinical
23
ATG (Fresenius Biotech)Astellas PharmaPhase 2
52
Advagraf + Prograf + PrografAstellas PharmaApproved
85
Prograf + AdvagrafAstellas PharmaApproved
85
Prograf + MR4Astellas PharmaPhase 3
77
tacrolimus modified release (MR) + tacrolimusAstellas PharmaPhase 2
52
tacrolimus modified release (MR) + tacrolimusAstellas PharmaPhase 2
52
tacrolimusAstellas PharmaPhase 3
77
Prograf-XL + Prograf + MMFAstellas PharmaPhase 3
77
micafungin + fluconazole + liposomal amphotericin B + caspofunginAstellas PharmaPhase 3
77
Tacrolimus granules + Tacrolimus granulesAstellas PharmaApproved
85
FK506E (modified release tacrolimus) + Prograf (tacrolimus)Astellas PharmaPhase 3
77
FK778Astellas PharmaPhase 2
52
Tacrolimus modified-release + PrografAstellas PharmaPhase 3
77
Advagraf + PrografAstellas PharmaApproved
85
Prograf + FK506MR capsuleAstellas PharmaPhase 3
77